Hospital

Elranatamab enhances MRD negativity in relapsed/refractory multiple myeloma post idecabtagene vicleucel, promising improved treatment outcomes.

Expert discusses groundbreaking studies on the on-body injector for isatuximab, highlighting its efficacy, safety, and patient convenience.

Pharmacists enhance patient care in multiple myeloma by focusing on infection prevention, CRS management, and optimizing outcomes with T-cell engagers post-CAR T.

Belantamab mafodotin with bortezomib shows promising survival benefits for lenalidomide-refractory multiple myeloma patients.

Idecabtagene vicleucel shows a lower infection risk than other BCMA therapies for multiple myeloma.

Costimulatory bispecific antibodies revolutionize multiple myeloma treatment, offering deeper responses and flexible sequencing strategies for patients.

New findings reveal that combining daratumumab with lenalidomide significantly enhances MRD negativity and progression-free survival in multiple myeloma maintenance therapy.

Linvoseltamab combined with carfilzomib shows promising results in treating relapsed/refractory multiple myeloma.

The approval is supported by findings from the MK-3475A-D77 study.

Experts discuss the potential of linvoseltamab in treating high-risk smoldering multiple myeloma, highlighting promising early trial results and response rates.

Intravenous immunoglobulin (IVIG) treatment significantly reduces infection rates in multiple myeloma patients receiving BCMA bispecific antibodies, showcasing its clinical benefits.

Outpatient use of bispecifics and CAR T-cell therapies in multiple myeloma can expand access.

Teclistamab shows promising results in frontline multiple myeloma treatment, achieving high MRD negativity rates, but safety concerns remain.

Teclistamab and other bispecific antibodies enhance multiple myeloma treatment but significantly increase infection risks, necessitating proactive management strategies.

The latest antibiotic therapies and guidelines offer effective strategies for managing carbapenem-resistant Acinetobacter baumannii infections

Teclistamab shows promising results in newly diagnosed multiple myeloma, enhancing tolerability and achieving high rates of minimal residual disease negativity.

Long-term care pharmacists are significant in lessening the vaccine hesitancy hurdle among facility residents.

Elranatamab combined with daratumumab and lenalidomide shows promising results for treating newly diagnosed multiple myeloma, enhancing patient outcomes.

Fluctuations in glycemic delta, a specific measurement of glucose levels, is an indicator of worsened myocardial infarction outcomes, including greater reductions in left ventricular ejection fraction.

An expert discusses the benefits of anti-CD38 quadruplet regimens for elderly multiple myeloma patients.

An expert discusses CAR T therapy's potential in treating relapsed multiple myeloma, highlighting long-term remissions and access challenges.

An expert discusses the promising results of elranatamab as a consolidative therapy for relapsed/refractory multiple myeloma, enhancing patient outcomes.

NCCN updated its small-cell lung cancer guidelines, introducing lurbinectedin for maintenance therapy and removing the chemotherapy-free interval for better treatment strategies.

Cemiplimab was also superior in improving progression-free survival, objective response rate, and duration of response in patients with non–small cell lung cancer (NSCLC).

The 2025 International Myeloma Society Annual Meeting unveils crucial updates to IMWG guidelines, enhancing response assessment and treatment strategies for multiple myeloma.

A recent study highlights the AOV dual-chamber system as a faster, safer option for RSV vaccine reconstitution, enhancing efficiency for health care providers.

Digitoxin reduces primary composite vs placebo in HFrEF, with no statistically significant effect on individual components of all-cause mortality or first heart failure-related hospitalization.

Cutting-edge insights and expert discussions on multiple myeloma will be presented at the 2025 IMS Annual Meeting in Toronto, shaping future treatment standards.